You just read:

Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder

News provided by

Eisai Co., Ltd.

Mar 07, 2018, 07:08 ET